Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity.
Alemtuzumab, a monoclonal anti-CD52 antibody has been shown to be highly effective in B-cell chronic lymphocytic leukemia, even in fludarabine-refractory disease. The mechanism of action is currently unknown, but may rely on complement-mediated cell lysis and antibody-dependent cellular cytotoxicity. The aim of this study was to assess the proapoptotic activity of alemtuzumab in chronic lymphocytic leukemia and to describe pathways potentially underlying this effect. Peripheral blood mononuclear cells from 21 chronic lymphocytic leukemia patients were treated in vitro in the absence of complement with fludarabine alone, alemtuzumab alone, or with the additional presence of a cross-linking anti-Fc-antibody. Apoptosis was quantified after 24 h by flow cytometry analysis. Expression of several pro- and anti-apoptotic proteins was determined at different time points. Apoptosis of peripheral blood mononuclear cells treated with alemtuzumab alone was significantly enhanced compared to untreated cells suggesting a minor potentially cytotoxic mechanism by direct signaling independent from antibody-dependent cellular cytotoxicity. The presence of a cross-linking anti-Fc-antibody induced the formation of cell clusters and enhanced apoptosis significantly suggesting a potential role of antibody-dependent cellular cytotoxicity in alemtuzumab induced apoptosis. Alemtuzumab activated a CD52-dependent signaling pathway which induced a significant increase in caspase 3 and 8 expression. Alemtuzumab significantly enhances apoptosis in chronic lymphocytic leukemia cells in vitro, especially in combination with a cross-linking anti-Fc-antibody, this effect being mediated by a caspase-dependent pathway.
Nückel
Holger
H
Department of Hematology, Medical School, University of Duisburg-Essen, Germany. holger.nueckel@uni-essen.de
Frey
Ulrich H
UH
Röth
Alexander
A
Dührsen
Ulrich
U
Siffert
Winfried
W
D000074323:Alemtuzumab; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D001402:B-Lymphocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D015153:Blotting, Western; D053148:Caspase 3; D053453:Caspase 9; D020169:Caspases / Q000378:metabolism; D002449:Cell Aggregation / Q000187:drug effects; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D015451:Leukemia, Lymphocytic, Chronic, B-Cell / Q000097:blood / Q000473:pathology; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000276:immunology / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D014740:Vidarabine / Q000031:analogs & derivatives* / Q000494:pharmacology; D051028:bcl-2-Associated X Protein
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; D000074323:Alemtuzumab; C505407:CASP3 protein, human; C506433:CASP9 protein, human; D053148:Caspase 3; D053453:Caspase 9; D020169:Caspases; D014740:Vidarabine; C024352:fludarabine